AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Jordi Rodon'
:
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
Publication Year: 2018
DOI: https://doi.org/10.18632/oncotarget.25854
Abstract:
Add to Library
Authors:
Jordi Rodón
Giuseppe Curigliano
Jean‐Pierre Delord
Wael A. Harb
Analía Azaro
Yu Han
Celine Wilke
V Donnet
Dalila Sellami
Thaddeus Beck
Unveiling changes in the landscape of patient populations in cancer early drug development
Publication Year: 2016
DOI: https://doi.org/10.18632/oncotarget.13258
Abstract:
Add to Library
Authors:
Cinta Hierro
Analía Azaro
Guillem Argilés
Elena Élez
Patricia Gómez
Joan Carles
Jordi Rodón
Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
Publication Year: 2014
DOI: https://doi.org/10.1158/1538-7445.am2014-ct325
Abstract:
Add to Library
Authors:
Rodrigo Dienstmann
Rastilav Bahleda
Bárbara Adamo
Jordi Rodón
Andréa Varga
Anas Gazzah
Suso Platero
Hans Smit
Timothy Perera
Bob Zhong
Kim Stuyckens
Yusri Elsayed
Chris H. Takimoto
Vijay Peddareddigari
Josep Tabernero
Feng Luo
Jean‐Charles Soria
Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors
Publication Year: 2015
DOI: https://doi.org/10.1158/1535-7163.targ-15-c45
Abstract:
Add to Library
Authors:
Filip Janků
Roisín M. Connolly
Patricia LoRusso
Maya de Jonge
Ulka N. Vaishampayan
Jordi Rodón
Guillem Argilés
Andrea P. Myers
Shu‐Fang Hsu Schmitz
Yan Ji
Margaret E. McLaughlin
Michael R. Palmer
Jennifer Morawiak
Abstract CT001: Neratinib in <i>HER2</i> or <i>HER3</i> mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
Publication Year: 2017
DOI: https://doi.org/10.1158/1538-7445.am2017-ct001
Abstract:
Add to Library
Authors:
David M. Hyman
Sarina A. Piha‐Paul
Jordi Rodón
Cristina Saura
Geoffrey I. Shapiro
David I. Quinn
Víctor Moreno
Ingrid A. Mayer
Carlos L. Arteaga
Valentina Boni
Emiliano Calvo
Sherene Loi
A. Craig Lockhart
Lillian M. Smyth
Joseph P. Erinjeri
Maurizio Scaltriti
Gary A. Ulaner
Jean Torrisi
Juber Patel
Jiabin Tang
Fanli Meng
Duygu Selcuklu
Helen Won
Nancy Bouvier
Michael F. Berger
Richard E. Cutler
Feng Xu
Anna Butturini
Lisa D. Eli
Grace Mann
Alshad S. Lalani
Richard Bryce
Funda Meric‐Bernstam
José Baselga
David B. Solit
Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-ct020
Abstract:
Add to Library
Authors:
Katherine C. Kurnit
Funda Meric‐Bernstam
Kenneth R. Hess
Robert L. Coleman
Priya Bhosale
Katerina V. Savelieva
Filip Janků
David S. Hong
Aung Naing
Shubham Pant
Jordi Rodón
Timothy A. Yap
Anil K. Sood
Pamela T. Soliman
David M. Gershenson
Gordon B. Mills
Shannon N. Westin
Abstract CT175: Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct175
Abstract:
Add to Library
Authors:
Jordi Rodón
Guillem Argilés
Roisín M. Connolly
Ulka N. Vaishampayan
Maja De Jonge
Elena Garralda
Marios Giannakis
David Smith
Jason R. Dobson
Margaret E. McLaughlin
Abdelkader Seroutou
Yan Ji
S. Ranieri Dolan
Jennifer Morawiak
Susan E. Moody
Filip Janků
Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.
Publication Year: 2013
DOI: https://doi.org/10.1158/1538-7445.am2013-lb-65
Abstract:
Add to Library
Authors:
Jordi Rodón
Dejan Juric
Ana-Maria Gonzalez-Angulo
Johanna C. Bendell
Jordan Berlin
Douglas Bootle
Kathlene Gravelin
Alan Huang
Adnan Derti
Joseph Lehár
Jens Würthner
Markus Boehm
Eliezer M. Van Allen
Nikhil Wagle
Levi A. Garraway
Roman Yelensky
Philip J. Stephens
Vincent A. Miller
Robert Schlegel
Cornelia Quadt
José Baselga
Abstract 974: Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.am2021-974
Abstract:
Add to Library
Authors:
Siqing Fu
Shuyang Yao
Yuan Yuan
Rebecca A. Previs
Anthony Elias
Richard D. Carvajal
Thomas J. George
Ying Yuan
Yuko Yamamura
Shannon N. Westin
Yan Xing
Ecaterina E. Dumbrava
Daniel D. Karp
Sarina A. Piha‐Paul
Apostolia M. Tsimberidou
Jordi Rodón
Naoko Takebe
Charles A. Kunos
Karen H. Lu
Khanda Keyomarsi
Funda Meric‐Bernstam
Abstract CT016: Clinical and translational findings of pemigatinib in previously treated solid tumors with activating <i>FGFR1-3</i> alterations in the FIGHT-207 study
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.am2023-ct016
Abstract:
Add to Library
Authors:
Jordi Rodón
Silvia Damian
Muhammad Furqan
Jesús García-Donás
Hiroo Imai
Antoîne Italiano
Iben Spanggaard
Makoto Ueno
Tomoya Yokota
L. Véronèse
Natália Cristina de Oliveira
Xin Li
Aidan G. Gilmartin
Lipika Goyal
Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors
Publication Year: 2015
DOI: https://doi.org/10.1158/1535-7163.targ-15-b25
Abstract:
Add to Library
Authors:
Jordi Rodón
Aurelius Omlin
K.H. Herbschleb
Javier García-Corbacho
Jan Steiner
Ignacio Dolado
Christof Zitt
Daniel Feurstein
D. Turner
Keith M. Dawson
H Binz
Patrick Gilboy
A. Harstrick
Analía Azaro
Christoph Ackermann
Mark R. Middleton
Richard D. Baird
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
Publication Year: 2015
DOI: https://doi.org/10.18632/oncotarget.3741
Abstract:
Add to Library
Authors:
Vladimir Lazar
Eitan Rubin
Stéphane Depil
Yudi Pawitan
Jean‐François Martini
Jesús Gómez-Navarro
Antoine Yver
Zhengyin Kan
Jonathan R. Dry
Jeanne Kehren
Pierre Validire
Jordi Rodón
Philippe Vielh
Michel Ducreux
Susan Galbraith
M. Lehnert
Amir Onn
Raanan Berger
Marco A. Pierotti
Angel Porgador
C S Pramesh
Dingwei Ye
André Lopes Carvalho
Gerald Batist
Thierry Le Chevalier
Philippe Morice
Benjamin Besse
Gilles Vassal
Andrew A. Mortlock
Johan Hansson
Ioana Berindan‐Neagoe
Robert Dann
Joel Haspel
Alexandru Irimie
Steve Laderman
Hovav Nechushtan
Amal Al‐Omari
Trent Haywood
Catherine Bresson
Khee‐Chee Soo
Iman Osman
Hilario Mata
John Lee
Komal Jhaveri
Guillaume Meurice
Gary A. Palmer
Ludovic Lacroix
Serge Koscielny
Karina Eterovic
Jean‐Yves Blay
Richard E. Buller
Alexander Eggermont
Richard L. Schilsky
John Mendelsohn
Jean‐Charles Soria
Mace L. Rothenberg
Jean‐Yves Scoazec
Waun Ki Hong
Razelle Kurzrock
Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)
Publication Year: 2018
DOI: https://doi.org/10.1158/1535-7163.targ-17-a094
Abstract:
Add to Library
Authors:
Wassim Abida
Yung Jue Bang
Louise Carter
Analía Azaro
Matthew Krebs
Seock‐Ah Im
Chen Ying-xue
Núria Buil‐Bruna
Yan Li
David Eaton
C. Stephens
Graham Ross
Martin Pass
Jordi Rodón
Emma Dean
Abstract B005: A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
Publication Year: 2019
DOI: https://doi.org/10.1158/1535-7163.targ-19-b005
Abstract:
Add to Library
Authors:
Diana M. Lopez
Minal Barve
Judy Wang
Andrea J. Bullock
Eirini Pectasides
Ulka N. Vaishampayan
Alexander I. Spira
Susanna V. Ulahannan
Amita Patnaik
Rachel E. Sanborn
Dragan Cicic
Qiuqing Ang
Gregory Bergonio
Jordi Rodón
Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct024
Abstract:
Add to Library
Authors:
Shubham Pant
Vivek Subbiah
Jordi Rodón
Filip Janků
David S. Hong
Daniel D. Karp
Sarina A. Piha‐Paul
Apostolia M. Tsimberidou
Aung Naing
Siqing Fu
Ron Savage
Fang Chai
Yi Yu
Brian Schwartz
Funda Meric‐Bernstam
T.A. Yap
Found 150 results in 0.07 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"